Introduction and Objectives: The number of sensor-detected hypoglycemia (SDH) episodes depends on the hypoglycemia threshold used. We investigated the relationship between glucose threshold and the number and duration of events in the Hypo-METRICS dataset.

Methods: Individuals with insulin-treated diabetes wore a blinded continuous glucose monitor for 10 weeks. SDH was defined as 15 min below each threshold between 5 mmol/L (90 mg/dL) and 2.2 mmol/L (40 mg/dL) at 0.1 mmol/L increments. The number and average duration of episodes was calculated at each glucose threshold.

Results: Data from 599 (T1D=276 and T2D=323) people were analyzed; median age 56 years, HbA1c 7.4%. Event rate was higher for events between 3-5 mmol/L than < 3mmol/L (10.5 vs 1.1 episodes/week, p < 0.01) and average duration longer (63.1 vs 35.5 minutes/episode, p < 0.01). This is shown in Figure 1a and b. Each 0.1 mmol/L increment in hypoglycemia threshold resulted in 0.5 more episodes/week between 3-5 mmol/L vs 0.05 additional episodes/week at a threshold < 3 mmol/l (p < 0.01). Each 0.1 mmol/l increment in hypoglycemia threshold increased average duration by 3.1 minutes/episode between 3-5 mmol/l vs 0.4 minutes/episodes for those < 3 mmol/l (p < 0.01).

Conclusion: These results may be useful in understanding the alarm burden at different thresholds allowing personalization in proportion to individual risks.

Disclosure

J.J.C. Thomas: None. V. Koutroukas: Other Relationship; KelCon GmbH. P. Divilly: None. G. Martine-Edith: Other Relationship; Novo Nordisk A/S. N. Zaremba: None. S.A. Amiel: Advisory Panel; Vertex Pharmaceuticals Incorporated. Other Relationship; Sanofi. P. Choudhary: Advisory Panel; Abbott, Biolinq. Speaker's Bureau; Dexcom, Inc., Eli Lilly and Company, Novo Nordisk, Sanofi. Advisory Panel; Ypsomed AG, Vertex Pharmaceuticals Incorporated.

Funding

Hypo-RESOLVE (the consortium to which the Hypo-METRICS study belongs) has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777460. Abbott Diabetes Care providedthe continuous glucose monitors used in the study

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.